Scarica l'app Stockscreener
20.52
6.81%
-1.50
Dopo l'orario di chiusura:
20.53
0.01
+0.05%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SRPT Giù?
Forum
Previsione
Frazionamento azionario
Sarepta Therapeutics Inc Borsa (SRPT) Ultime notizie
Sarepta Therapeutics Drops 5.5% Amid Sector-Wide Selling - AlphaStreet
This Analyst Sees 34% Upside For SRPT Stock — Here's Why They Expect A Sustained Rally Next - Stocktwits
SRPT Looks 79.1% Undervalued on GF Value™ Despite Profitability Challenges - GuruFocus
Sarepta Therapeutics climbs 10%, rebounding from recent slide (SRPT:NASDAQ) - Seeking Alpha
Caleres Posts Upbeat Q2 Earnings, Joins Opus Genetics, Flotek Industries And Other Big Stocks Moving High - Benzinga
H.C. Wainwright reiterates Sarepta stock Sell rating at $5 target By Investing.com - Investing.com Canada
Sarepta (NASDAQ: SRPT) CFO now holds 121,792 shares after tax withholding - Stock Titan
Tax on stock award trims Sarepta (NASDAQ: SRPT) EVP stake to 115,519 shares - Stock Titan
Sarepta (SRPT) COO reports tax share withholding after RSU vesting - Stock Titan
Jefferies reiterates Sarepta Therapeutics stock rating on trial data outlook By Investing.com - Investing.com South Africa
Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers - Reuters
A Rivals Clinical Stumble Sends Sarepta Therapeutics Stock Lower - Benzinga
Mizuho reiterates Sarepta stock rating after Novartis trial miss By Investing.com - Investing.com South Africa
Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 Academic Year - BioSpace
Why is Sarepta Therapeutics stock sliding today? By Investing.com - Investing.com Canada
Why is Sarepta Therapeutics stock sliding today? - Investing.com
Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Benzinga
Novartis drops 13% on trial failure, dragging Dyne and Sarepta (NVS:NYSE) - Seeking Alpha
TSLA: Tesla Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Sarepta Therapeutics (SRPT) Stock Analysis: Navigating the Biotech Landscape with Innovative Therapies - DirectorsTalk Interviews
Capricor Or Sarepta: Two DMD Stocks Enter A High-Stakes Week – Which One Has More Upside? - Stocktwits
SRPT Stock Snaps Hot Winning Streak Ahead Of Q4 Print — What Bear Positioning And Big Money Are Signaling - Stocktwits
Sarepta Therapeutics Faces Investor Investigations – 8-5 - stl.news
Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc.SRPT - PR Newswire
Why Is Sarepta Therapeutics (SRPT) Up 37% Since Last Earnings Report? - Yahoo Finance
Sarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference - finance.yahoo.com
Sarepta Therapeutics, Inc. (SRPT) Stock Analysis: Potential Upside In Biotech Amidst Revenue Challenges - DirectorsTalk Interviews
Sarepta Therapeutics (SRPT) Could Be 30% Undervalued After Elevidys Progress Hopes - Sahm
Sarepta: A Prove-It Story Now Defined By ELEVIDYS Execution - Seeking Alpha
SRPT On Track For Best Week In 5 Months Ahead Of Late-2026 Clinical Data — Retail Eyes ‘Monumental Comeback’ - Stocktwits
Sarepta (SRPT) Stock Looks Fully Valued As Sales Trail Fair Value - Yahoo Finance
SRPT Stock Plunges 7% After-Hours As Elevidys Demand Slumps — CEO Still Sees Return To Growth - Stocktwits
Sarepta Therapeutics Delivers Q2 Operating Profit as CEO Transition Advances Pipeline - Streetwise Reports
Sarepta Therapeutics Jumps 8.6% Amid Sector-Wide Rally - AlphaStreet
Sarepta Therapeutics (NASDAQ:SRPT) Shares Up 9.2%Here's Why - MarketBeat
Sarepta Awaits New FDA Challenge as Trump Chooses Heidi Overton - TechStock²
SRPT|Sarepta Therapeutics Inc|Price:19.220|Chg%:-0.510 - TradingKey
Sarepta Therapeutics Stock Short Interest Falls to 31.28% - Quiver Quantitative
Sarepta Shares Rise As Company Begins Enrollment In Gene Therapy Safety Enhancement Study - Stocktwits
Sarepta Hits Fresh Hurdle As Court Revives Patent Lawsuit With Regenxbio Over Muscular Disorder Therapy - Stocktwits
GSA Capital Partners LLP Purchases New Holdings in Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Sarepta Therapeutics, Inc. (SRPT) Stock Analysis: 22% Potential Upside Amidst Innovative Gene Therapy Developments - DirectorsTalk Interviews
Sarepta Therapeutics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
SRPT6155802 Latest News and Headlines - TradingView
Sarepta Stock Dips After Hours: DMD Drug Blow And CEO Exit Eclipse Q4 Revenue Beat - Stocktwits
Sarepta Therapeutics (NASDAQ:SRPT) Upgraded to "Hold" at Zacks Research - MarketBeat
Sarepta Therapeutics (SRPT) submits Form 13F showing one entry and $0 value - Stock Titan
Massachusetts Biotech's Flagship Gene Therapy Posts Fifth Straight Quarterly Decline as Muscular Dystrophy Data Loom - Streetwise Reports
Sarepta Therapeutics (SRPT) sees 5.05% ownership reported by AQR in 13G/A - Stock Titan
Bank of America Corp DE Increases Stock Position in Sarepta Therapeutics, Inc. $SRPT - MarketBeat
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):